FDA makes it easier for biosimilars to obtain interchangeability designations

The FDA on Thurs­day be­gan eas­ing the process for biosim­i­lar de­vel­op­ers to demon­strate in­ter­change­abil­i­ty with their brand-name bi­o­log­ics.

The agency pre­vi­ous­ly re­quired stud­ies to prove …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.